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Introduction 
In 2010, the United Nation’s Secretary General launched the Global Strategy for Women’s and 
Children’s Health to catalyze the efforts of governments, international agencies and 
organizations, foundations, academia, civil society, NGOs, businesses and professional 
associations to save 16 million women‘s and children‘s lives by 2015 (1).   To help accomplish 
this goal, the Global Strategy called for greater investment in innovations and the 
establishment of mechanisms such as the Grand Challenges initiative ‘Saving Lives at Birth’ and 
the Innovation Working Group to foster new technological developments with the potential to 
improve service quality and access (1,2). 
It is estimated that this enabling environment has fostered the emergence of more than 1000 
innovations for reproductive, maternal and child health which are now in the early 
development or pilot testing phase (1,2).  The ultimate impact of these technologies on global 
health will depend upon how rapidly and successfully they can be transitioned from the 
prototype phase to large scale manufacturing and distribution (2). 
The steps involved in this transition, from design to adoption to wide-scale introduction, should 
be evidence-based. The evidence generation process must provide the information needed to 
guide product development with the aim of addressing an unmet need, to ensure timely 
regulatory approval and market development, and to increase the likelihood of patient and 
provider acceptance and uptake (2,3,4,5).   
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We present here an outline of the clinical evidence generation plan for the BD Odon Device™ 
that will enable a more rapid and coordinated generation of the evidence needed to transition 
the device from design to adoption compared with traditional incremental approaches to 
product development and dissemination.  Such an approach, if proven successful, could be 
adapted for other emerging technologies in the future.  (5,6,7,8). 
Proposed solution 
The BD Odon Device is an innovative instrument for assisted vaginal birth with potential for 
preventing maternal, fetal and newborn deaths due to complicated second stage of labor. As 
with other developing global health technologies in the maternal and child health space, 
evidence is needed to: 
• Retire and mitigate during product development all possible envisaged risks to assure 
the highest standard of safety, especially considering that beneficiaries will be vulnerable 
populations such as mothers, fetuses and infants. 
• Define the target product profile that describes the medical indications for use and how 
the product will be used safely and effectively by the intended users. 
• Prove that the device compares favorably in terms of safety, efficacy, cost/benefit and 
acceptability with other available technologies when tested in controlled trials and real life 
conditions to facilitate its adoption and use at global level.  
While showing measurable clinical benefits remains a priority for regulatory purposes, evidence 
from clinical studies is increasingly required for other objectives such as reimbursement and 
procurement decisions, marketing and dissemination strategies and adoption (9). This need will 
be even more pressing for new global health technologies which can be scaled up only through 
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collaborative commercialization strategies based on public–private partnerships among 
industry, academic centers, nongovernmental organizations, foundations and governments 
(2,3,4). Solid evidence will be needed to motivate each stakeholder participating in this 
collaborative development and commercialization model to prioritize the investment of often 
scarce resources.   
A single study is very unlikely to address all objectives related to product development, 
regulatory approval, marketing and dissemination strategies and adoption.  However, it is 
important to avoid conducting fragmented and loosely related studies that would slow down 
the overall process of technology development and introduction and add to its costs, negatively 
impacting on affordability and access. Therefore, we have developed a comprehensive plan 
that will progressively generate the evidence needed by conducting a series of sequential and 
coordinated non-clinical, preclinical and clinical studies. The sequential approach will include 
milestones that have to be achieved prior to the decision to proceed to the next phase (9).   
The clinical evidence generation plan addresses three major needs which are the drivers of the 
development strategy: 1) define the target product profile, 2) obtain regulatory approval and 3) 
support marketing and dissemination and adoption. 
The definition of the target product profile aims at describing how the BD Odon Device should 
be safely and effectively used. Evidence is needed to develop device design features to assure 
effectiveness and safety before comparing it with available alternatives for assisted vaginal 
birth in randomized clinical trials. To achieve this objective, after completing non-clinical studies 
(bench testing for robustness, toxicity and durability), a series of preclinical studies (animal and 
simulation studies and human factors studies) were conducted.  
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Fulfillment of acceptance criteria for the preclinical studies will be the prerequisite to conduct a 
pivotal study (randomized clinical trial) that will generate the evidence to assess efficacy and 
safety of the product for registration purposes (CE Mark will be the first regulatory approval 
followed by country specific approvals). The pivotal study will be designed to fulfill recently 
proposed recommendations for rigorous -regulatory approval studies (10) and to provide data 
to support adoption.  The pivotal study will also provide an initial indication that the device 
could be used by midwives in settings where they are allowed to perform assisted vaginal birth.  
If the acceptance criteria for the pivotal study are met (i.e. the BD Odon Device is not inferior in 
efﬁcacy and safety to a selected currently available instrument for assisted vaginal birth), 
country specific pivotal studies and post market studies will be conducted with the objective of 
obtaining registration in countries with specific regulatory requirements. These additional 
studies will align with recent recommendations for systemic long-term assessment of safety 
and efficacy by facilitating identification of any additional potential risks that might emerge only 
after the device has been tested in real-world conditions (10).  
The global community has developed a new Global Strategy for Women’s, Children’s and 
Adolescent’s Health to carry the momentum forward into the next 15 years (11).  Although 
considerable reductions in maternal, newborn, and child mortality were accomplished under 
the Millennium Development Goal framework and significant commitments were made 
following the launch of the first Global Strategy in 2010, more progress is needed in ending 
preventable maternal and newborn deaths.  This unfinished agenda must continue to be 
prioritized as part of efforts to achieve the more ambitious development agenda enshrined in 
the Sustainable Development Goal framework.  The BD Odon Device represents an important 
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innovation in the area of assisted vaginal birth that could significantly contribute to this global 
goal.  
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